GMED
Globus Medical Inc Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$78.05Close
$60.39 – $96.8252-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 39 · weaker than 61% of stocks over 12 months
- Earnings shrinking EPS −26% year on year
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
down 4.1%
price change
1mo
up 4.2%
price change
12-month return
up 29%
market up 11% ·
its own up 16%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 17%
year on year
EPS growth
down 26%
latest quarter · -92 pts
Sales growth
up 6%
latest quarter · -21 pts
ROE
up 12%
return on equity
Free cash margin
up 20%
$588.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.7×
net cash
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Gross margin 58.9% → 67.4%
Trade setup
ATR%
2.9%
$2.28 a day · 2×ATR $73.49
RS
39 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
0.91
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- Price above the 50-day average: passes
- Within 25% of the 52-week high: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+2% vs market2 sessions after results
Financials
- Gross 67%
- Net 18%
- Free cash 20%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $789.0M | $958.1M | $1.0B | $1.6B | $2.5B | $2.9B |
| Gross margin | 72% | 75% | 74% | 65% | 59% | 67% |
| Operating income | $111.4M | $172.0M | $228.0M | $133.1M | $166.0M | $479.8M |
| Net income | $102.3M | $149.2M | $190.2M | $122.9M | $103.0M | $537.9M |
| Net margin | 13% | 16% | 19% | 8% | 4% | 18% |
| Earnings per share | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| Free cash flow | $135.1M | $219.4M | $104.4M | $165.2M | $405.2M | $588.8M |
| Free cash margin | 17% | 23% | 10% | 11% | 16% | 20% |
| Cash | $239.4M | $193.1M | $150.5M | $467.3M | $784.4M | $526.2M |
| Shareholders' equity | $1.5B | $1.7B | $1.8B | $4.0B | $4.2B | $4.6B |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 23, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 24, 2026 | Results ↗ |
| Jan 7, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jul 21, 2025 | Results · Director or officer change · Regulation FD ↗ |
| Jun 5, 2025 | Director or officer change · Shareholder vote ↗ |
| May 15, 2025 | Other events ↗ |
| May 8, 2025 | Results ↗ |